Tentarix Biotherapeutics, Inc

4 articles about Tentarix Biotherapeutics, Inc

• Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million

  9/6/2023

  Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.

• Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation

  8/15/2023

  Gilead Sciences, Inc. and Tentarix Biotherapeutics announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.

• Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams

  5/20/2022

  Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team.

• 

  Money on the Move: October 13 – 19

  10/20/2021

  Investors can take their pick of life sciences companies, with more innovative ideas and treatments being added to pipelines daily. Here's who brought in the sheaves this week.